CHOSOURCE™ expression platform

The CHOSOURCE™ expression platform enables rapid identification of clones expressing high levels of recombinant therapeutic protein during development of a stable cell line.

Flexible licensing terms ensure this high-performance platform is easily accessible to meet the demands of cost-effective biomanufacturing.

Clear intellectual property position ensures freedom to operate in biotherapeutic production.

Why choose CHOSOURCE?

Industry standard with a proven track record

• Easy-to-use CHO-K1 GS knockout cells have been widely adopted for bioproduction/manufacturing
• More than 100 CHOSOURCE licenses sold worldwide since 2016 launch
• 20 confirmed clinical laboratory regulatory submissions filed globally in the past 2 years
• Ability to reach high expression levels – customers routinely report >4g/L with different molecules
• Full history, traceability, IP clear and freedom-to-operate technology

Truly adaptable platform

• Validated with different feeds, media, processes, molecules and vector technologies
• Flexible, attractive pricing to meet your needs
• Widely used Glutamine Synthetase (GS) selection is the gold standard for selection systems

Dedicated Horizon team

• Accessible sales, licensing and scientific support teams to simplify purchase and setup
• Extensive expertise using the platform to drive advancements in your pipeline

The CHOSOURCE expression platform consists of:

• CHO-K1 GS knockout cell line (Cat #: HD-BIOP3)
  Well established, cGMP manufactured robust Glutamine Synthetase knockout CHO-K1 cell line produced using precision rAAV technology
• Dual promoter expression vector
  Enables expression of an entire mAb from a single vector
• Comprehensive protocols
• Cell line history package to support regulatory submissions
  Fully documented traceable history of R&D and manufacture of the CHO-K1 GS KO cell line